We manufacture, market and sell a total of 33 pharmaceutical products in the PRC. We also manufacture 11 types of APIs, most of which are manufactured for self-use. Taking into account our anticipated products in the future, we generally categorise our products into the following key therapeutic areas: anti-viral products, products for the treatment of endocrine and metabolic diseases, products for the treatment of cardiovascular diseases and other products. Currently, our top five products by turnover are: Kewei, Oumeining, Xinhaining, Ertongshu and Xining.
Anti-viral products are products used for the treatment and prevention of virus infections, such as influenza. As at the Latest Practicable Date, we manufacture and sell 7 anti-viral products in the PRC, with the most significant product being Kewei (oseltamivir phosphate). The granules form of Kewei was introduced by the Group with a view to target the paediatrics market in the PRC and we are the only manufacturer of the patent-protected granule form oseltamivir phosphate in the PRC, which has allowed us to secure a strong position in the anti-influenza virus product market in the PRC. In the PRC, oseltamivir phosphate is recommended by NHFPC as the first choice medicine to treat H1N1 influenza, as well as H7N9 influenza. As a designated supplier of oseltamivir phosphate to the Central Medical Reserve (中央醫(yī)藥儲(chǔ)備基地), we have successfully supplied to the PRC Government and the military and has been recognised by them accordingly. In 2004, we participated in the oseltamivir phosphate research program conducted by the Poisons and Drugs Research Office of the Medical Science Academy of the PRC People’s Liberation Army (中國(guó)人民解放軍軍事醫(yī)學(xué)科學(xué)院毒物藥物研究所) (“Poisons and Drugs Research Office”), and was jointly responsible for conducting laboratory research, small scale production, medium scale production and commercial production in connection thereof. When the H1N1 influenza A outbreak occurred and spread globally in April 2009, as the designated supplier of oseltamivir phosphate to the military, we actively cooperated with the Government’s relevant taskforce and successfully supplied oseltamivir phosphate products to them. In this connection, we efficiently and timely completed the supply of oseltamivir phosphate products to the government, and have received a recognition letter from the NDRC for this.
Benzbromarone is a drug used for the treatment of excess uric acid in blood (hyperuricemia), which could often lead to gout. Gout is a medical condition usually characterised by recurrent attacks of acute inflammatory arthritis and often affects a person’s feet and toes. Our benzbromarone tablets are marketed under the name “Ertongshu” (爾同舒), and the use of benzbromarone products for the treatment of excess levels of uric acids and gouts have been recognised by various medical associations.For example, The British Society for Rheumatology has recognised the use of benzbromarone for managing recurrent, intercritical and chronic gouts. In the PRC, the Endocrine Studies Sub-Association of the Chinese Medical Association (中華醫(yī)學(xué)會(huì)內(nèi)分泌學(xué)分會(huì)) has also recognised benzbromarone products as an effective treatment against patients with excess levels of uric acids and for gouts.
Telmisartan is an angiotensin II receptor antagonist used for the treatment and prevention of hypertension. In the PRC, we market our telmisartan tablets under the name “Oumeining”(歐美寧). This drug is used for patients with high blood pressure and works by relaxing blood vessels to help reduce blood pressure. The American Society for Hypertension and the International Society for Hypertension have recognised the use of angiotensin II receptor blockers (ARBs) as one of the main treatments for managing hypertension. In the PRC, according to the 2010 Chinese Guidelines for the Management of Hypertension (中國(guó)高血壓防治指南2010), clinical trials have indicated that telmisartan is effective in managing the blood pressure levels of patients with hypertension.
Amlodipine besylate is used for the treatment and prevention of hypertension and chest pains, as well as the treatment of artery diseases. In the PRC, we market amlodipine besylate tablets under the name “Xinhaining” (欣海寧). This drug is used for patients with hypertension and belongs to a class of drugs known as “calcium channel blockers”.The American Society for Hypertension and the International Society for Hypertension has recognised the use of calcium channel blockers as one of the main treatments for managing hypertension. In the PRC, according to the 2010 Chinese Guidelines for the Management of Hypertension (中國(guó)高血壓防治指南2010), clinical trials have indicated that amlodipine is effective in managing the blood pressure levels of patients with hypertension.
Cetirizine hydrochloride is a generic drug used for the treatment of hay fever, allergies, colds and swelling. In the PRC, we market our cetirizine hydrochloride disersing tablets under the name “Xining” (喜寧).Cetirizine hydrochloride is a second-generation antihistamine and is particularly effective in relieving allergies by blocking the relevant receptors that causes the relevant symptoms. It produces selective inhibition of peripheral histamine (H1) receptors which serve to reduce or eliminate effects mediated by histamine, an endogenous chemical mediator released during allergic reactions. Cetirizine hydrochloride belongs to second generation of H1-antihistamines which are newer drugs that are much more selective for peripheral H1 receptors than to the central nervous system H1 receptors or cholinergic receptors. This selectivity significantly reduces the occurrence of adverse events, such as sedation, while still providing effective relief of allergic conditions.
